

21 October 2021

## Treatment of Lung Cancer

### 1 In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

• Afatinib :	0
• Alectinib :	2
• Atezolizumab monotherapy :	2
• Atezolizumab with chemotherapy :	0
• Bevacizumab :	0
• Brigatinib :	0
• Ceritinib :	0
• Crizotinib :	1
• Dacomitinib :	0
• Dabrafenib with Trametinib :	0
• Docetaxel monotherapy or combination with Carboplatin/Cisplatin :	0
• Durvalumab :	1
• Erlotinib :	0
• Gefitinib :	1
• Gemcitabine (+Carboplatin) :	5
• Lorlatinib :	1
• Nintedanib with Docetaxel :	0
• Nivolumab :	0
• Osimertinib :	8
• Paclitaxel :	0
• Pembrolizumab monotherapy :	25

21 October 2021

- Pembrolizumab with chemotherapy : 9
- Pemetrexed with Carboplatin/Cisplatin : 2
- Vinorelbine with Carboplatin/Cisplatin : 21
- Any other active systemic anti-cancer therapy (SACT) : CARBO AUC6 : 3
- Palliative care only: Not available via RISOH

**2 In the past 3 months, how many patients were treated for squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:**

- Atezolizumab monotherapy: 0
- Atezolizumab with chemotherapy : 0
- Durvalumab 1
- Gemcitabine (+Carboplatin) :3
- Nivolumab: 0
- Osimertinib : 0
- Paclitaxel : 0
- Pembrolizumab (Keytruda) Mono : 4
- Pembrolizumab (Keytruda) with Chemotherapy : 7
- Other active systemic anti-cancer therapy (SACT): Carboplatin/Vinorelbine +/- XRT : 10
- Palliative care only: Not available via RISOH

21 October 2021

**3 Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?**

Project Short title	Project Full title	Patients recruited	Status
ADSCaN.	A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-small Cell Lung Cancer.	3	Closed to recruitment - patients on follow up
SMP2	The Cancer Research UK Stratified Medicine Programme: Pilot Study	133	Closed to recruitment 30/09/21
FAK-PD1 v1	(FAK-PD1) A Phase I/IIA study to assess safety, tolerability and preliminary activity of the combination of FAK (defactinib) and PD-1 (pembrolizumab) inhibition in patients with advanced solid malignancies	3	Open
HALT - Stereotactic Body Radiotherapy for the treatment of OPD	Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours	1	Open
National Lung Matrix: Multi-Drug Phase II trial in NSC Lung Cancer	National Lung Matrix Trial: Multi--drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer	0	Open

21 October 2021

SARON	Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A randomised phase III trial.	0	Recruitment on hold
TOPIC 2	A Randomised Controlled Trial to investigate the effectiveness of Thoracic Epidural and Paravertebral Blockade In reducing Chronic Post- Thoracotomy Pain: 2	5	Open